Radioimmunotherapy and colorectal cancer
Background: Despite the success of radioimmunotherapy (RIT) using radiolabelled monoclonal antibodies (Mabs) directed against tumour‐associated antigens in the treatment of non‐Hodgkin's lymphoma, therapeutic success in solid tumours has been modest. In the past decade, a dozen Mabs have been i...
Gespeichert in:
| Veröffentlicht in: | British journal of surgery 2005-03, Vol.92 (3), p.264-276 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 276 |
|---|---|
| container_issue | 3 |
| container_start_page | 264 |
| container_title | British journal of surgery |
| container_volume | 92 |
| creator | Koppe, M. J. Bleichrodt, R. P. Oyen, W. J. G. Boerman, O. C. |
| description | Background:
Despite the success of radioimmunotherapy (RIT) using radiolabelled monoclonal antibodies (Mabs) directed against tumour‐associated antigens in the treatment of non‐Hodgkin's lymphoma, therapeutic success in solid tumours has been modest. In the past decade, a dozen Mabs have been investigated clinically for their potential usefulness in RIT of colorectal cancer.
Methods:
The application of radiolabelled Mabs for the treatment of solid cancers is discussed, and clinical trials investigating RIT for colorectal cancer listed in the Medline and Embase databases are reviewed.
Results:
Uptake of radiolabelled Mabs in tumour and, consequently, the therapeutic efficacy of RIT is inversely correlated with tumour size. The bone marrow is the most important dose‐limiting organ. Twenty‐three phase I/II studies were found that investigated the feasibility and efficacy of RIT using five radionuclides and 15 Mabs against carcinoembryonic antigen, tumour‐associated glycoprotein 72, epithelial cellular adhesion molecule, A33 or colon‐specific antigen p, mainly in patients with advanced colorectal cancer. A few responses were recorded but no particular antibody construct seemed superior.
Conclusion:
RIT might be an effective adjuvant treatment modality in colorectal cancer. Future studies should focus on its application in patients with small‐volume or minimal residual disease. Copyright © 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
May be worthwhile for small‐volume disease |
| doi_str_mv | 10.1002/bjs.4936 |
| format | Article |
| fullrecord | <record><control><sourceid>istex_pubme</sourceid><recordid>TN_cdi_pubmed_primary_15739250</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_XKLG5D97_S</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4546-32d720a2fc5bbdda006688eead31bbc5206f5fcca47aedeb3ac1e9763d8eefba3</originalsourceid><addsrcrecordid>eNpF0EtPAjEUBeDGaATRxF9g2Ji4Gbxtpy2zVFB8EE1Eo7vm9jFxcIYhLUT59w4BZXUW98vNySHklEKPArBLM429NONyj7QplyJhVPb3SRsAVEI54y1yFOMUgHIQ7JC0qFA8YwLa5OIFXVEXVbWc1YtPH3C-6uLMdW1d1sHbBZZdizPrwzE5yLGM_mSbHfJ2e_M6uEvGz6P7wdU4salIZcKZUwyQ5VYY4xwCSNnve4-OU2OsYCBzkVuLqULvvOFoqc-U5K5BuUHeIWebv_OlqbzT81BUGFb6r3IDzrcAo8UyD029Iu6cFFkqM9G4ZOO-i9KvdnfQ68l0M5leT6avHybr3PkiLvzPv8fwpaXiSuj3p5H-eByPxDBTesJ_Ab_BbSg</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Radioimmunotherapy and colorectal cancer</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Koppe, M. J. ; Bleichrodt, R. P. ; Oyen, W. J. G. ; Boerman, O. C.</creator><creatorcontrib>Koppe, M. J. ; Bleichrodt, R. P. ; Oyen, W. J. G. ; Boerman, O. C.</creatorcontrib><description>Background:
Despite the success of radioimmunotherapy (RIT) using radiolabelled monoclonal antibodies (Mabs) directed against tumour‐associated antigens in the treatment of non‐Hodgkin's lymphoma, therapeutic success in solid tumours has been modest. In the past decade, a dozen Mabs have been investigated clinically for their potential usefulness in RIT of colorectal cancer.
Methods:
The application of radiolabelled Mabs for the treatment of solid cancers is discussed, and clinical trials investigating RIT for colorectal cancer listed in the Medline and Embase databases are reviewed.
Results:
Uptake of radiolabelled Mabs in tumour and, consequently, the therapeutic efficacy of RIT is inversely correlated with tumour size. The bone marrow is the most important dose‐limiting organ. Twenty‐three phase I/II studies were found that investigated the feasibility and efficacy of RIT using five radionuclides and 15 Mabs against carcinoembryonic antigen, tumour‐associated glycoprotein 72, epithelial cellular adhesion molecule, A33 or colon‐specific antigen p, mainly in patients with advanced colorectal cancer. A few responses were recorded but no particular antibody construct seemed superior.
Conclusion:
RIT might be an effective adjuvant treatment modality in colorectal cancer. Future studies should focus on its application in patients with small‐volume or minimal residual disease. Copyright © 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
May be worthwhile for small‐volume disease</description><identifier>ISSN: 0007-1323</identifier><identifier>EISSN: 1365-2168</identifier><identifier>DOI: 10.1002/bjs.4936</identifier><identifier>PMID: 15739250</identifier><identifier>CODEN: BJSUAM</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antigens, Neoplasm - metabolism ; Biological and medical sciences ; Carcinoembryonic Antigen - metabolism ; Cell Adhesion Molecules - metabolism ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Colorectal Neoplasms - metabolism ; Colorectal Neoplasms - radiotherapy ; Dose-Response Relationship, Radiation ; Gastroenterology. Liver. Pancreas. Abdomen ; General aspects ; Glycoproteins - metabolism ; Humans ; Medical sciences ; Membrane Glycoproteins - metabolism ; Radioimmunotherapy - methods ; Radioisotopes - adverse effects ; Radioisotopes - therapeutic use ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tumors</subject><ispartof>British journal of surgery, 2005-03, Vol.92 (3), p.264-276</ispartof><rights>Copyright © 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.</rights><rights>2005 INIST-CNRS</rights><rights>Copyright (c) 2005 British Journal of Surgery Society Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4546-32d720a2fc5bbdda006688eead31bbc5206f5fcca47aedeb3ac1e9763d8eefba3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fbjs.4936$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fbjs.4936$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16594695$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15739250$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koppe, M. J.</creatorcontrib><creatorcontrib>Bleichrodt, R. P.</creatorcontrib><creatorcontrib>Oyen, W. J. G.</creatorcontrib><creatorcontrib>Boerman, O. C.</creatorcontrib><title>Radioimmunotherapy and colorectal cancer</title><title>British journal of surgery</title><addtitle>Br J Surg</addtitle><description>Background:
Despite the success of radioimmunotherapy (RIT) using radiolabelled monoclonal antibodies (Mabs) directed against tumour‐associated antigens in the treatment of non‐Hodgkin's lymphoma, therapeutic success in solid tumours has been modest. In the past decade, a dozen Mabs have been investigated clinically for their potential usefulness in RIT of colorectal cancer.
Methods:
The application of radiolabelled Mabs for the treatment of solid cancers is discussed, and clinical trials investigating RIT for colorectal cancer listed in the Medline and Embase databases are reviewed.
Results:
Uptake of radiolabelled Mabs in tumour and, consequently, the therapeutic efficacy of RIT is inversely correlated with tumour size. The bone marrow is the most important dose‐limiting organ. Twenty‐three phase I/II studies were found that investigated the feasibility and efficacy of RIT using five radionuclides and 15 Mabs against carcinoembryonic antigen, tumour‐associated glycoprotein 72, epithelial cellular adhesion molecule, A33 or colon‐specific antigen p, mainly in patients with advanced colorectal cancer. A few responses were recorded but no particular antibody construct seemed superior.
Conclusion:
RIT might be an effective adjuvant treatment modality in colorectal cancer. Future studies should focus on its application in patients with small‐volume or minimal residual disease. Copyright © 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
May be worthwhile for small‐volume disease</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antigens, Neoplasm - metabolism</subject><subject>Biological and medical sciences</subject><subject>Carcinoembryonic Antigen - metabolism</subject><subject>Cell Adhesion Molecules - metabolism</subject><subject>Clinical Trials, Phase I as Topic</subject><subject>Clinical Trials, Phase II as Topic</subject><subject>Colorectal Neoplasms - metabolism</subject><subject>Colorectal Neoplasms - radiotherapy</subject><subject>Dose-Response Relationship, Radiation</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>General aspects</subject><subject>Glycoproteins - metabolism</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins - metabolism</subject><subject>Radioimmunotherapy - methods</subject><subject>Radioisotopes - adverse effects</subject><subject>Radioisotopes - therapeutic use</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tumors</subject><issn>0007-1323</issn><issn>1365-2168</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0EtPAjEUBeDGaATRxF9g2Ji4Gbxtpy2zVFB8EE1Eo7vm9jFxcIYhLUT59w4BZXUW98vNySHklEKPArBLM429NONyj7QplyJhVPb3SRsAVEI54y1yFOMUgHIQ7JC0qFA8YwLa5OIFXVEXVbWc1YtPH3C-6uLMdW1d1sHbBZZdizPrwzE5yLGM_mSbHfJ2e_M6uEvGz6P7wdU4salIZcKZUwyQ5VYY4xwCSNnve4-OU2OsYCBzkVuLqULvvOFoqc-U5K5BuUHeIWebv_OlqbzT81BUGFb6r3IDzrcAo8UyD029Iu6cFFkqM9G4ZOO-i9KvdnfQ68l0M5leT6avHybr3PkiLvzPv8fwpaXiSuj3p5H-eByPxDBTesJ_Ab_BbSg</recordid><startdate>200503</startdate><enddate>200503</enddate><creator>Koppe, M. J.</creator><creator>Bleichrodt, R. P.</creator><creator>Oyen, W. J. G.</creator><creator>Boerman, O. C.</creator><general>John Wiley & Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200503</creationdate><title>Radioimmunotherapy and colorectal cancer</title><author>Koppe, M. J. ; Bleichrodt, R. P. ; Oyen, W. J. G. ; Boerman, O. C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4546-32d720a2fc5bbdda006688eead31bbc5206f5fcca47aedeb3ac1e9763d8eefba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antigens, Neoplasm - metabolism</topic><topic>Biological and medical sciences</topic><topic>Carcinoembryonic Antigen - metabolism</topic><topic>Cell Adhesion Molecules - metabolism</topic><topic>Clinical Trials, Phase I as Topic</topic><topic>Clinical Trials, Phase II as Topic</topic><topic>Colorectal Neoplasms - metabolism</topic><topic>Colorectal Neoplasms - radiotherapy</topic><topic>Dose-Response Relationship, Radiation</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>General aspects</topic><topic>Glycoproteins - metabolism</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins - metabolism</topic><topic>Radioimmunotherapy - methods</topic><topic>Radioisotopes - adverse effects</topic><topic>Radioisotopes - therapeutic use</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koppe, M. J.</creatorcontrib><creatorcontrib>Bleichrodt, R. P.</creatorcontrib><creatorcontrib>Oyen, W. J. G.</creatorcontrib><creatorcontrib>Boerman, O. C.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>British journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koppe, M. J.</au><au>Bleichrodt, R. P.</au><au>Oyen, W. J. G.</au><au>Boerman, O. C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radioimmunotherapy and colorectal cancer</atitle><jtitle>British journal of surgery</jtitle><addtitle>Br J Surg</addtitle><date>2005-03</date><risdate>2005</risdate><volume>92</volume><issue>3</issue><spage>264</spage><epage>276</epage><pages>264-276</pages><issn>0007-1323</issn><eissn>1365-2168</eissn><coden>BJSUAM</coden><abstract>Background:
Despite the success of radioimmunotherapy (RIT) using radiolabelled monoclonal antibodies (Mabs) directed against tumour‐associated antigens in the treatment of non‐Hodgkin's lymphoma, therapeutic success in solid tumours has been modest. In the past decade, a dozen Mabs have been investigated clinically for their potential usefulness in RIT of colorectal cancer.
Methods:
The application of radiolabelled Mabs for the treatment of solid cancers is discussed, and clinical trials investigating RIT for colorectal cancer listed in the Medline and Embase databases are reviewed.
Results:
Uptake of radiolabelled Mabs in tumour and, consequently, the therapeutic efficacy of RIT is inversely correlated with tumour size. The bone marrow is the most important dose‐limiting organ. Twenty‐three phase I/II studies were found that investigated the feasibility and efficacy of RIT using five radionuclides and 15 Mabs against carcinoembryonic antigen, tumour‐associated glycoprotein 72, epithelial cellular adhesion molecule, A33 or colon‐specific antigen p, mainly in patients with advanced colorectal cancer. A few responses were recorded but no particular antibody construct seemed superior.
Conclusion:
RIT might be an effective adjuvant treatment modality in colorectal cancer. Future studies should focus on its application in patients with small‐volume or minimal residual disease. Copyright © 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
May be worthwhile for small‐volume disease</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>15739250</pmid><doi>10.1002/bjs.4936</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1323 |
| ispartof | British journal of surgery, 2005-03, Vol.92 (3), p.264-276 |
| issn | 0007-1323 1365-2168 |
| language | eng |
| recordid | cdi_pubmed_primary_15739250 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antibodies, Monoclonal - therapeutic use Antigens, Neoplasm - metabolism Biological and medical sciences Carcinoembryonic Antigen - metabolism Cell Adhesion Molecules - metabolism Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Colorectal Neoplasms - metabolism Colorectal Neoplasms - radiotherapy Dose-Response Relationship, Radiation Gastroenterology. Liver. Pancreas. Abdomen General aspects Glycoproteins - metabolism Humans Medical sciences Membrane Glycoproteins - metabolism Radioimmunotherapy - methods Radioisotopes - adverse effects Radioisotopes - therapeutic use Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors |
| title | Radioimmunotherapy and colorectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T13%3A20%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radioimmunotherapy%20and%20colorectal%20cancer&rft.jtitle=British%20journal%20of%20surgery&rft.au=Koppe,%20M.%20J.&rft.date=2005-03&rft.volume=92&rft.issue=3&rft.spage=264&rft.epage=276&rft.pages=264-276&rft.issn=0007-1323&rft.eissn=1365-2168&rft.coden=BJSUAM&rft_id=info:doi/10.1002/bjs.4936&rft_dat=%3Cistex_pubme%3Eark_67375_WNG_XKLG5D97_S%3C/istex_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/15739250&rfr_iscdi=true |